Adenocarcinoma of the Colon Clinical Trial
Official title:
Prospective Study of Oncologic Outcomes After Laparoscopic Modified Complete Mesocolic Excision for Non-metastatic Right Colon Cancer [PIONEER Study]: Multicenter, Single-Arm Study
This study is a multi-institutional, prospective, observational study evaluation oncologic
outcomes of laparoscopic modified complete mesocolic excision (mCME) on right-sided colon
cancer.
The primary outcome of this study is 3 year disease-free survival. Secondary outcome measures
include 3 year overall survival, incidence of surgical complications, completeness of mCME,
and distribution of metastatic lymph nodes.
The present study aims to evaluate the oncological outcomes of laparoscopic mCME on
right-sided colon cancer. The right side of the colon was defined as the colon from cecum up
to the proximal half of the transverse colon. The number of patients needs to get a 90% power
is 250. Patients will be enrolled at five leading centers in South Korea. A complete
information leaflet will give to the patients during the first consultation, which will
correspond to the enrollment day. The preoperative, intraoperative, and postoperative period
will be in complete accordance with the usual care of the center. The baseline demographics
and conditions, as well as the perioperative items and the postoperative occurrences, will be
recorded through a prior designed case report form. The follow-up encompasses 13
postoperative consultations: 1month, 3 months, after that every 3 months until 36 months.
The primary outcome of this study is 3-year disease-free survival. Secondary outcome measures
include 3-year overall survival, the incidence of surgical complications, completeness of
mCME, and distribution of metastatic lymph nodes. Review of resected surgical specimens and
the operative field after completion of lymph node dissection will be done based on
photographs to assess the quality if surgery.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01455831 -
Extended Peri-operative Tinzaparin to Improve Disease-free Survival in Patients With Resectable Colorectal Cancer
|
Phase 3 | |
Completed |
NCT00025337 -
Combination Chemotherapy With or Without Bevacizumab Compared With Bevacizumab Alone in Treating Patients With Advanced or Metastatic Colorectal Cancer That Has Been Previously Treated
|
Phase 3 | |
Completed |
NCT03871959 -
Pembrolizumab In Combination With Debio 1143 In Pancreatic and Colorectal Advanced/Metastatic Adenocarcinoma
|
Phase 1 | |
Recruiting |
NCT05080673 -
Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps
|
N/A | |
Completed |
NCT01037790 -
Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer
|
Phase 2 | |
Completed |
NCT00707889 -
Phase 2 Study of ABT-869 in Combination With mFOLFOX6 Versus Bevacizumab in Combination With mFOLFOX6 to Treat Advanced Colorectal Cancer
|
Phase 2 | |
Completed |
NCT00551421 -
Pertuzumab and Cetuximab in Treating Patients With Previously Treated Locally Advanced or Metastatic Colorectal Cancer
|
Phase 1/Phase 2 | |
Terminated |
NCT00052585 -
Gefitinib and Combination Chemotherapy in Treating Patients With Advanced or Recurrent Colorectal Cancer
|
Phase 2 | |
Completed |
NCT00023933 -
Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Recurrent or Persistent Metastatic Colorectal Cancer
|
Phase 1 | |
Terminated |
NCT00397878 -
AZD0530 (NSC 735464) in Treating Patients With Previously Treated Metastatic Colon Cancer or Rectal Cancer
|
Phase 2 | |
Completed |
NCT00028496 -
Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer
|
Phase 1 | |
Recruiting |
NCT04005118 -
Human Intestinal Microbiome and Surgical Outcomes in Patients Undergoing Colorectal Cancer Surgery
|
||
Completed |
NCT00003835 -
Combination Chemotherapy in Treating Patients With Stage III Colon Cancer
|
Phase 3 | |
Terminated |
NCT02425683 -
Study of Colorectal Cancer Patients (Stage IIIC) With Either Regorafenib or Standard of Care (No Treatment) After Adjuvant FOLFOX
|
Phase 2 | |
Recruiting |
NCT05669430 -
A Study of GV20-0251 in Patients With Solid Tumor Malignancies
|
Phase 1 | |
Completed |
NCT00005818 -
SU5416 and Irinotecan in Treating Patients With Advanced Colorectal Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT04624555 -
The Utility and Feasibility of Mt-sDNA as a Surveillance Procedure in Colorectal Cancer Survivors
|
||
Terminated |
NCT01606124 -
Polyphenon E in Treating Patients With High-Risk of Colorectal Cancer
|
Phase 2 | |
Completed |
NCT00942266 -
Vorinostat, Fluorouracil, and Leucovorin Calcium in Treating Patients With Metastatic Colorectal Cancer That Has Not Responded to Previous Treatment
|
Phase 2 | |
Recruiting |
NCT05197322 -
NEOadjuvant PembRolizumab In Stratified Medicine - ColoRectal Cancer
|
Phase 2 |